GSK announced a major breakthrough concerning cancer therapy. A drug called Jemperli (dostarlimab) showed impressive results in a phase 2 trial at the Memorial Sloan Kettering Cancer Center (MSK).

Bret Hulick was in his second year of medical school at LECOM in Erie, analyzing the case of a 24-year-old colon cancer ...

In what can be termed a never-seen-before medical miracle, a small group of people with colorectal cancer achieved 100% ...

The drugmaker remains convinced of the potential of the drug, however, and has just reported results of a trial comparing Jemperli (dostarlimab ... non-small cell lung cancer (NSCLC) that has ...

This trial is looking at dostarlimab by itself and with other immunotherapies ... GSK6097608 is another monoclonal antibody that blocks a protein called CD96 on the cancer cells. Research shows that a ...

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its ... GSK's PD-1 inhibitor Jemperli (dostarlimab). The total value of the deal could ...

Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced today the dose administration for the first patient in a Phase 2 trial for its experimental drug ...